Kupferminc M J, Lessing J B, Amit A, Yovel I, David M P, Peyser M R
IVF Unit, Serline Maternity Hospital, Sakler School of Medicine, Tel-Aviv University, Israel.
Hum Reprod. 1990 Apr;5(3):271-3. doi: 10.1093/oxfordjournals.humrep.a137087.
A randomized, prospective blind study was carried out to investigate the need for luteal phase support in patients undergoing in-vitro fertilization (IVF). One-hundred-and-fifty-six patients undergoing IVF in cycles stimulated with human menopausal gonadotropin (HMG) and human chorionic gonadotrophin (HCG) stimulated IVF, were divided into three different groups for luteal phase treatment. Fifty-four patients received dydrogesterone three times daily (TID) beginning on the day of embryo transfer (ET). Fifty-one patients received HCG on days 3, 6 and 10 following ET. Fifty-one patients received placebo p.o. TID beginning on the day of ET. There was no difference between the groups in pregnancy rate, rate of spontaneous abortion, proportion of normally developing fetuses or rate of chemical pregnancy. The data indicate that supplementation of the luteal phase may not improve the success rates of IVF-ET cycles.
开展了一项随机、前瞻性盲法研究，以调查体外受精（IVF）患者黄体期支持的必要性。156例接受人绝经期促性腺激素（HMG）和人绒毛膜促性腺激素（HCG）刺激的IVF周期患者，被分为三组进行黄体期治疗。54例患者从胚胎移植（ET）日开始每天口服三次地屈孕酮（TID）。51例患者在ET后的第3、6和10天接受HCG。51例患者从ET日开始每天口服三次安慰剂。各组在妊娠率、自然流产率、正常发育胎儿比例或生化妊娠率方面无差异。数据表明，黄体期补充可能不会提高IVF-ET周期的成功率。
